What advances have been made in immune therapy for renal cell carcinoma? Discover what the experts say in this opinion article from Future Oncology.
To mark Rare Disease Day, Oncology Central brings you an exclusive opinion piece written by two of the principal investigators of a pivotal immunotherapy clinical trial designed specifically for rare cancer patients.
Following the continuing evolution of cancer immunotherapy, this featured article discusses how image-guided, minimally invasive therapies and immuno-oncology agents may be combined – could there be resultant synergy between these two modalities?
This exclusive opinion piece debates the use of therapeutic agents already established for other conditions for the treatment of cancer.
Join us as we look back at 2016 on Oncology Central, reviewing some of the topics and data within oncology that really got you talking over the course of the last year.
Could long-noncoding RNAs be utilized as novel circulating biomakers to aid the detection, diagnosis and prognosis of melanoma?
Dr Hafez Halawani talks to Oncology Central regarding the predictive and prognostic potential of tumor location in metastatic colorectal cancer – a debate that was perpetuated with the presentation of the Venook et al study at the 2016 ASCO meeting.
As World Cancer Research Fund UK marks its 25th anniversary, founder and President Marilyn Gentry gives us her thoughts on its work as a trailblazer in the field of cancer prevention, and its future in terms of both research and health policy.
Read further about how the CRUK Centre for Drug Development (CDD) helps to take promising clinical drug candidates from academic sources and commercial partners into early-phase clinical trials.